Noxopharm Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Gisela Mautner

Chief executive officer

AU$491.6k

Total compensation

CEO salary percentage83.4%
CEO tenure2.6yrs
CEO ownershipn/a
Management average tenure3.7yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation

Aug 24
Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Jul 22
We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Feb 27
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Nov 10
We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Jun 04
Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 17
Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Sep 04
These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

CEO Compensation Analysis

How has Gisela Mautner's remuneration changed compared to Noxopharm's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-AU$4m

Mar 31 2024n/an/a

-AU$8m

Dec 31 2023n/an/a

-AU$12m

Sep 30 2023n/an/a

-AU$14m

Jun 30 2023AU$492kAU$410k

-AU$15m

Mar 31 2023n/an/a

-AU$15m

Dec 31 2022n/an/a

-AU$15m

Sep 30 2022n/an/a

-AU$17m

Jun 30 2022AU$1mAU$201k

-AU$19m

Compensation vs Market: Gisela's total compensation ($USD329.40K) is about average for companies of similar size in the Australian market ($USD305.54K).

Compensation vs Earnings: Gisela's compensation has been consistent with company performance over the past year.


CEO

Gisela Mautner

2.6yrs

Tenure

AU$491,562

Compensation

Dr. Gisela Mautner is Non-Executive Director of Nyrada Inc. from August 1, 2022. She serves as Director at Noxopharm Limited. She served as Chief Medical Officer at Noxopharm Limited since October 2019 unt...


Leadership Team

NamePositionTenureCompensationOwnership
Gisela Mautner
CEO, Executive MD & Director2.6yrsAU$491.56kno data
Shawn Van Boheemen
Chief Financial Officer5.4yrsno datano data
Jeanette Bell
Chief Operating Officer4.7yrsno datano data
John Wilkinson
Chief Scientific Officer of Oncology2.7yrsno datano data
Olivier Laczka
Chief Scientific Officer of Inflammation2.7yrsno datano data
David Franks
Company Secretary7.7yrsAU$16.49kno data

3.7yrs

Average Tenure

Experienced Management: NOX's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gisela Mautner
CEO, Executive MD & Directorno dataAU$491.56kno data
Frederick Bart
Non-Executive Chairman4.3yrsAU$45.00k2.57%
A$ 735.8k
Peter Marks
Non-Executive Deputy Chairman8.5yrsAU$60.00k0.31%
A$ 88.2k
Boris Patkin
Non-Executive Director4.5yrsAU$56.69k0.22%
A$ 61.7k

4.5yrs

Average Tenure

70yo

Average Age

Experienced Board: NOX's board of directors are considered experienced (4.5 years average tenure).